THE COMBINATION OF VENETOCLAX AND IBRUTINIB IS EFFECTIVE IN RELAPSED/REFRACTORY T‐PROLYMPHOCYTIC LEUKEMIA AND INFLUENCES BCL‐2‐FAMILY MEMBER DEPENDENCIES
Christoph Kornauth(Munich Leukemia Laboratory (Germany)), Philipp B. Staber(Vienna General Hospital), Charles Herbaux(Centre Hospitalier Universitaire de Lille), Matthew S. Davids(Dana-Farber Cancer Institute), Christine Guillemette(Université Laval), Stefan Kubicek(Austrian Academy of Sciences), Mathias Mayerhofer(Medical University of Vienna), Uli Jäger(Institute for Interdisciplinary Studies of Austrian Universities), Bernd Boidol(Austrian Academy of Sciences)
Cited by 10
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595